NCT00520169

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

A Randomized, Open Label, Single Center, Single-Dose, Cross-Over Study to Determine the Absolute Bioavailability and the Nasopharyngeal Absorption of PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Javelin Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

Detailed description

To examine the safety and assess the absolute bioavailability and nasopharyngeal absorption of PMI-150 30mg.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	intranasal ketamine	A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.

Timeline

• Start date: 2007-07-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2007-08-23
• Last updated: 2008-01-10

Locations

1 site across 1 country: United States